Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.

Biotech R&D: Apellis vs. Celldex - A Decade of Investment

__timestampApellis Pharmaceuticals, Inc.Celldex Therapeutics, Inc.
Wednesday, January 1, 20148379522104381000
Thursday, January 1, 201513730311100171000
Friday, January 1, 201622978599102726000
Sunday, January 1, 20174030387896171000
Monday, January 1, 201810528557666449000
Tuesday, January 1, 201922096877042672000
Wednesday, January 1, 202029992100042534000
Friday, January 1, 202142086900053311000
Saturday, January 1, 202238723600082258000
Sunday, January 1, 2023354387000118011000
Loading chart...

Data in motion

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Apellis Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D spending. Apellis Pharmaceuticals has shown a remarkable growth, with its R&D expenses surging by over 4,000% from 2014 to 2023. This reflects their commitment to pioneering treatments and expanding their therapeutic pipeline. In contrast, Celldex Therapeutics experienced a more modest increase of around 13% in the same period, indicating a more conservative approach. Notably, in 2023, Apellis's R&D investment was nearly three times that of Celldex, highlighting their aggressive strategy in the competitive biotech arena. This data underscores the dynamic nature of R&D investments and their critical role in driving innovation and growth in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025